Comparing the current results to its competitors, Affimed N V reported Revenue decrease in the 4 quarter 2023 year on year by -79.99 %, faster than the overall decrease of Affimed N V 's competitors by -0.35 %, recorded in the same quarter.
Affimed N V 's Comment on Competition and Industry Peers
The company competes with other sponsors conducting investigational therapies for enrolling patients in clinical studies. Its competitors include approved immunotherapies and investigational immunotherapies, such as new immuno-oncology drugs like checkpoint inhibitors (CPIs). The company's product candidate, acimtamig, has orphan drug designation for the treatment of Hodgkin lymphoma (HL) and T-cell lymphoma, which limits the patient population. Competitors may also obtain orphan product exclusivity for the same indications, potentially delaying the company's product approvals. The life sciences industry is highly competitive and rapidly evolving, with competitors developing products that may be more effective, safer, or less expensive, which could affect the company's commercial opportunities.
April 24, 2024
Affimed N.V., a clinical-stage immuno-oncology company, recently made an exciting announcement regarding the acceptance of its clinical abstract on AFM24 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. The abstract presents preliminary data from a phase 2 combination study of AFM24, an innate cell engager (ICE), in conjunction with atezolizumab, Roche s checkpoint inhibitor, for the treatment of EGFR-wildtype non-small cell lung cancer (NSCLC) patients.The study aims to evaluate the safety and efficacy of combining AFM24 with atezolizumab for patients with EGFR-wildtype NSCLC, a subset of lung cancer patients that lack specific genetic mutations in the EGFR gene. The data presentatio...
January 8, 2024
Affimed N.V., a leading clinical-stage immuno-oncology company, has recently provided an update on the clinical response data for its ongoing AFM24-102 phase 1/2a study in EGFRwt NSCLC (epidermal growth factor receptor-wildtype non-small cell lung cancer). With a commitment to empowering patients in their fight against cancer, Affimed s groundbreaking research and development efforts have shown promising results in this challenging disease.Update on AFM24-102 Clinical Response DataThe latest clinical response data from the AFM24-102 trial offers renewed hope to patients suffering from EGFRwt NSCLC, a particular subset of lung cancer that is known to be more difficult to treat. The study evaluates the efficac...
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Madrigal Pharmaceuticals Inc's business model is focused on developing and commercializing innovative therapeutic solutions for liver diseases, with a particular emphasis on non-alcoholic steatohepatitis (NASH) and other metabolic diseases. They aim to provide effective treatments to address unmet medical needs and improve patient outcomes in these areas.
Cytodyn Inc is a biotechnology company that focuses on the development and commercialization of innovative treatments for a range of diseases, including cancer and viral infections. The company primarily generates revenue through the licensing and sale of its therapeutics to medical institutions and pharmaceutical companies. Cytodyn's business model revolves around the research and development of novel drugs, conducting clinical trials, and forming strategic partnerships to bring their innovative treatments to market.
Nurix Therapeutics Inc's business model involves developing targeted protein degradation therapies to treat diseases by modulating the body's cellular protein levels.
Supernus Pharmaceuticals Inc operates under a unique business model focused on the development and commercialization of innovative treatments for central nervous system (CNS) diseases. The company combines in-house expertise with strategic partnerships to efficiently advance and bring their products to market. By prioritizing CNS disorders and utilizing a collaborative approach, Supernus Pharmaceuticals strives to address unmet medical needs and improve the lives of patients.
Sources:
Affimed N v’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Affimed N v versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
